EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Return of Clinically Actionable Pharmacogenetic Results From Molecular Tumor Board DNA Sequencing Data: Workflow and Estimated Costs

Hyunwoo Koo iD, Tayler B Smith, John T Callaghan iD, Wilberforce Osei, Steven M Bray, Emma M Tillman iD, Mya T Tran iD, Christopher A Fausel, Bryan P Schneider, Tyler Shugg iD, Todd C Skaar

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3545 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Hyunwoo Koo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Pharmacogenomic Testing, Neoplasms, Pharmacogenetics, Pharmacogenomic Variants. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacogenetic testing can prevent severe toxicities from several oncology drug therapies; it also has the potential to improve the outcomes from supportive care drugs. Paired tumor and germline sequencing is increasingly common in oncology practice; these include sequencing of pharmacogenes, but the germline pharmacogenetic variants are rarely included in the clinical reports, despite many being clinically actionable. We established an informatics workflow to evaluate the clinical sequencing results for pharmacogenetic variants. We used the Aldy computational tool, which we have previously shown to determine the variant alleles in 14 pharmacogenes in clinical sequencing data with >99% accuracy, to identify pharmacogenetic variants in the clinical whole exome sequencing from our molecular tumor board. Patients with genetic variants that are clinically actionable for their individual therapy programs, including both treatment and supportive care, are referred to a clinical pharmacogenetics testing laboratory for confirmation. Through an evaluation of our weekly informatics workflow, we determined it took approximately 3.25 hours to complete the analysis of the sequencing data from approximately 20 patients. Using a United States pharmacist's median salary, we estimated the incremental added cost of the process to be only ~$15 per patient. This adds only a minor increase to the patient's cost of testing and has the potential to improve the safety and efficacy of their treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pharmacogenomic TestingNeoplasmsPharmacogeneticsPharmacogenomic VariantsSequence Analysis, DNAAntineoplastic AgentsHumansWorkflowExome Sequencing

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Department of Pharmacy Practice, Purdue University College of Pharmacy, West Lafayette, Indiana, USA.
  • Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • LifeOmic, Inc., Indianapolis, Indiana, USA.
  • Indiana University Health, Indianapolis, Indiana, USA.

ORCID-Profile: Hyunwoo Koo, John T Callaghan, Emma M Tillman, Mya T Tran, Tyler Shugg

Förderung

  • NIGMS NIH HHS

Zitieren

APA

Koo, H., Smith, T. B., Callaghan, J. T., Osei, W., Bray, S. M., Tillman, E. M., Tran, M. T., Fausel, C. A., Schneider, B. P., Shugg, T., & Skaar, T. C. (2025). Return of Clinically Actionable Pharmacogenetic Results From Molecular Tumor Board DNA Sequencing Data: Workflow and Estimated Costs. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3545

Vancouver

Koo H, Smith TB, Callaghan JT, Osei W, Bray SM, Tillman EM, et al. Return of Clinically Actionable Pharmacogenetic Results From Molecular Tumor Board DNA Sequencing Data: Workflow and Estimated Costs. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3545

BibTeX
@article{Koo2025,
  author = {Koo, Hyunwoo and Smith, Tayler B and Callaghan, John T and Osei, Wilberforce and Bray, Steven M and Tillman, Emma M and Tran, Mya T and Fausel, Christopher A and Schneider, Bryan P and Shugg, Tyler and Skaar, Todd C},
  title = {Return of Clinically Actionable Pharmacogenetic Results From Molecular Tumor Board DNA Sequencing Data: Workflow and Estimated Costs},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3545}
}
Kostenlos starten →